The incidence of immune-related adverse events (irAEs) and their association with clinical outcomes in advanced renal cell carcinoma and urothelial carcinoma patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis.
Yaowen ZhangJunru ChenHaoyang LiuJindong DaiJunjie ZhaoSha ZhuXingming ZhangJiayu LiangXu HuJinge ZhaoZhenhua LiuPengfei ShenGuangxi SunHao ZengPublished in: Cancer treatment reviews (2024)
Our findings suggest that the occurrence of irAEs could be considered as a potential prognostic factor for predicting the efficacy of ICIs in patients with advanced RCC and UC.